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SUMMARY Sun exposure is today well recognized as having an adverse 
effect on human skin. Part of sun radiation, ultraviolet radiation A (UVA) and 
B (UVB), can modify skin structures and induce short-term skin changes 
(sunburn, tanning, hyperkeratinization, brown spots) and long-term skin 
damages (accelerated skin aging and skin cancers). Protection against 
both UVA and UVB is very important, therefore sun protection by clothes, 
avoiding sun exposure and correct use of sunscreens are important means 
to reduce short- and long-term solar radiation effects. The recommendation 
of appropriate sunscreen by doctors and cosmetic professionals (the 
function of skin type and sun radiation intensity) is today easier due to 
the recently implemented European uniform labeling system of sunscreens 
and detailed information for consumers.
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 Sun avoidance and clothing are important 
means of protection against the sun. Sunscreens 
have been a more controversial strategy for sun 
protection but recent prospective studies have 
shown that correct sunscreen use is important for 
the prevention of wrinkles and skin cancers (1-3). 
The choice of an appropriate sunscreen is made 
according to the information labeled on the sun-
screen packs and tubes by the cosmetic industry. 
The main problem is that different labeling systems 
were used by different sunscreen manufacturers. 
This created real confusion among consumers. 
Recent European recommendations issued by the 
Comité de Liaison des Industries de la Parfumerie 
(COLIPA) (4) are now uniformly applied in Eu-
rope, making the choice for adapting sunscreens 
to each skin type or sun intensity easier. 
 The Sun Protection Factor (SPF) is an indica-
tor of the ability of sunscreens to protect against 
sunburn (sun-induced erythema) (5-7). SPF is an 
international recommended method, by COLIPA 
in Europe, by the Food and Drug Administration 
(FDA) in the United States, and also accepted 
in other countries such as Japan, Australia, etc. 
This method is based on the assessment of the 
Minimal Erythema Dose (MED) determined in vivo 
(in healthy volunteers), using a lamp with Solar 
Simulated Radiation (SSR) (reproducing the so-
lar radiation at 40° North latitude, in July, at 12 h) 
as the light-source. The method of calculation is 
the ratio between the protected MED and non-pro-
tected MED (Fig. 1). It is important to understand 
that SPF is a ratio indicating the property of a sun-
screen to protect against sunburn (the higher the 
number, the higher the power to protect against 
sunburn). SPF number must not be understood 
as “n minutes longer in the sun” or “n times more 
powerful protector”. SPF can also be determined 
in vitro (using an UV spectrophotometer) assess-
ing the product’s absorption range (Fig. 2). The 
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sunscreen is applied onto a perfectly transparent 
plastic screen. There is good correlation between 
the two methods (in vivo and in vitro). 
 For the SPF, COLIPA recommends categories 
of photoprotection, updated in 2007 (Table 1). All 
types of SPF tests use a standard quantity of sun-
screen (applied on the volunteers’ skin or on the 
plastic screen) of 2 mg/cm2. This amount is im-
posed by SPF standard test requirements, while 
the actual sunscreen SPF is lower as people apply 
an amount of 0.5 to 1 mg/cm² on the skin (1,2). For 
this reason, high SPF sunscreens must be used for 
sun sensitive skins or light skins (SPF above 50). 
Different authors or laboratories propose practical 
examples of correct quantities of sunscreen that 
are closest to the correct amount (2 mg of sun-
screen per cm2 of skin) for better protection: for 
the face area we need “around 2 fingertips” of 
sunscreen, for the whole body we need a quan-
tity of sunscreen in the “size of a golf-ball”. The 
quantities can also be measured in “teaspoons” as 
shown in Table 2. 
 In the meantime, it is important to emphasize 
that high SPF sunscreens do not prolong inten-
tional sunbathing and tanning. 
 Even though SPF is providing information on 
the attenuation of sunburn (meaning mainly good 
UVB protection), SPF gives no information on the 
sunscreen UVA attenuation. The Index of Pro-
tection (IP) is determined in vivo or in vitro, and 
concerns only one part of the UVs, UVB or UVA, 
the complete name labeled being IP UVB or IP 
UVA. The IP UVB in vivo or in vitro (usually la-
beled “IP”) is based on the same testing methods 
as described above for SPF (assessing the same 
“sunburn” attenuation by a sunscreen), with a dif-
ference that the light source emits only UVB. For 
this reason, the results are different than those of 
SPF for the same sunscreen: IP is always equal or 
higher than SPF. IP is not recommended for sun-
screen labeling anymore.
 The IP UVA in vivo or in vitro testing methods 
are numerous (phototoxic method, immediate pig-
mentation darkening (IPD), permanent pigmenta-
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Measures the Minimal Erythemal Dose (MED)
=
smallest UVB-UVA dose to obtain a skin redness (erythema)*
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Correct amount to apply: 2 mg of sunscreen per cm2 of skin
Recommended number of teaspoons of sunscreen (1 teaspoon = 5g)
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Sunscreens labeling in 2007 
(according to COLIPA updated requirements)
Table I
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tion darkening (PPD), etc.). All these methods use 
UV lamps and assess the quality of a sunscreen to 
specifically attenuate UVA radiation (Fig. 3). Cur-
rently, PPD is the recommended UVA test. 
 PPD method is an in vivo test that assesses 
skin darkening induced by UVA lamp, measuring 
the lowest dose able to induce a grayish skin color 
at 2 h (Minimal Pigmentary Dose (MPD)). This 
phenomenon (8) is a transitory skin-darkening 
occurring immediately upon UVA exposure as a 
slight gray-brown skin color, fading progressively 
and stabilizing after 2 h. The mechanism of this 
process is poorly understood, being probably re-
lated to spatial rearrangement of melanosomes in 
keratinocytes and photo-oxidation of the pre-ex-
isting melanin. PPD is a stable and reproducible 
testing method assessing UVA attenuation of a 
sun protector. 
 SPF and PPD numbers are different for the 
same sunscreen, for example: a very high protec-
tion sunscreen can have an SPF 50 and a PPD of 
25 (SPF measures attenuation of the sunburn and 
PPD attenuation of the skin darkening). Never-
theless, a good SPF to PPD balance must reflect 
perfect attenuation of both UVB and UVA. The 
European implemented SPF/PPP ratio is <3. This 
indicates good UVB-UVA protection and is labeled 
on the sunscreen tubes with a logo “UVA”. 
 SPF and PPD are not precise enough in pro-
viding information on the sunscreen quality to pro-
tect long-UVA radiation, which is the reason why 
critical wavelength is also part of the European 
Community recommended labeling items starting 
from 2007. Critical wavelength (λc) assesses sun-
screen absorption of long-UVAs using the same 
method as described above for SPF in vitro: λc 
is the wavelength at which the product absorp-
tion reaches 90% of its total absorption surface 
(Fig. 4).
 What indications provide SPF, PPD and criti-
cal wavelength? SPF and PPD indicate that the 
sunscreen is able to delay skin response after sun 
exposure (sunburn, transient pigmentation) com-
pared to unprotected skin, while λc indicates pro-
tection against long-UVA radiation. None of these 
factors indicates directly the protection against 
UV-induced skin cancer or wrinkles.
 In vivo long-term studies in humans concern-
ing UV-induced carcinogenesis are ethically unac-
ceptable, and the same holds for animal studies 
(the more so, results would be difficult to extrapo-
late to humans). 
 Several in vitro tests are used today as the 
comet test (cultured cells are UV-irradiated and 
compared to UV-protected cells, DNA of both 
cultured cells are examined under fluorescence 
microscope), oncoprotein p53 test (p53 is a hu-
man protein activated within cell nuclei upon UV-
induced damage; the presence of p53 is a marker 
of nucleus UV-aggression). These tests (and oth-
er tests focused on immunosuppression induced 
by the sun) permit an approach to the protection 
against the photo-induced mechanisms of skin 
cancer. For the time being, there is no official in-
ternational standard of these methods.
 Prospective studies in sunscreen users have 
shown that external photoprotection is important 
in reducing the risk of skin cancers induced by 
solar radiation (1-4), and that “safe tanning” is a 
contradiction in terms (tanning being considered 
today as a marker of skin-aggression by the sun). 
CONCLUSIONS 
 Medical recommendations and COLIPA re-
quirement implemented in 2007 on sunscreen use 
are as follows:
t.i. & a.g. 2007
UVA and Critical wavelength (lambda c - �c)
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IP UVA in vivo
UVA only
Measures the Minimal Pigmentary Dose (MPD)
=
smallest UVA dose to obtain a pigmentation
IP UVA = MPD  with photo-protectorMPD  without photo-protector
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- Sunscreen protection as reflected by SPF 
should be the primary consideration for sunscreen 
“potency”. Four classes of SPF simplify the mes-
sage for users.
- SPF labeled number must be associated with 
labeled results of in vivo test of UVA-attenuation: 
PPD. A balanced UVB-UVA protection must be 
revealed by the SPF/PPD ratio of a minimum or 
equal to 3 (labeled with the logo “UVA”). 
- The in vitro critical wavelength (λc) method is 
a criterion for anti long-UVA protection and should 
be minimum or equal to 370 nm.
- Correct and complete information for sun-
screen users must be included in the sunscreen 
leaflets/instructions for use or written on the 
packs. 
- High SPF and PPD sunscreens must not pro-
long intentional sunbath.
- Apply an adequate amount of sunscreen (2 
mg/cm2) on the exposed skin areas prior to sun 
exposure; re-apply every 2 h and after each bath.
- Tanning is not good; seek shade. 
Public education on sun avoidance, protective 
measures (wear UV-opaque hats, long-sleeve T-
shirts and sunglasses) and topical application of 
sunscreens with a balanced anti-UVA-UVB protec-
tion should reduce the incidence of sun-induced 
skin cancer in the world.
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